EUVIMEDEUVIMED entdecken
Crossref

Population Pharmacokinetics for Pediatric Extrapolation of GenSci006: A 3.75-mg Triptorelin Acetate Microsphere Formulation for Central Precocious Puberty

Kun Wang iD, Zhongyi Sun, Fengyan Xu, Lu Liu, Tianhong Luo, Weiwei Gao, Tangping Zhao, Guangli Ma, Xiaoyan Zhu

Clinical Pharmacokinetics · 2026-06 · 65 (6) · 849-861

DOI: 10.1007/s40262-026-01634-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 09.04.2026. Verfasst von Kun Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, 201120, China. kun.wang@shcscc.com. Hauptthemen laut MEDLINE: Triptorelin Pamoate, Puberty, Precocious, Models, Biological. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Changchun GeneScience.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: Triptorelin acetate microspheres are long-acting gonadotropin-releasing hormone (GnRH) agonist used for treating central precocious puberty (CPP). GenSci006 is a newly developed 3.75-mg formulation intended as a local alternative to Diphereline®. This study aimed to characterize the pharmacokinetics (PK) of GenSci006 using population pharmacokinetic (PopPK) modeling with pediatric extrapolation, to evaluate pharmacodynamic (PD) comparability, and to support a fixed-dose regimen for CPP. METHODS: This study comprised two components: (1) PopPK modeling and model-based simulation to characterize exposure and support pediatric extrapolation; and (2) a comparative pharmacodynamic assessment based on serum luteinizing hormone (LH) responses. RESULTS: The final PopPK model employed a three-compartment structure with mixed sequential absorption phases (two first-order and a zero-order absorption), capturing triptorelin's multiphasic release. Covariates, including weight, age, albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), serum creatinine, total bilirubin, and creatinine clearance, showed no significant effect on PK. Allometric scaling (exponents 0.75 for clearance [CL] and 1 for central volume distribution [V3]) was applied to simulate pediatric exposure. Simulations indicated that at a fixed 3.75-mg dose, exposure decreased with increasing weight, with an approximately 1.7-fold difference between the 20-30 kg and 40-50 kg groups. In the comparative PD analysis, serum LH exposure profiles were comparable between GenSci006 and the reference product over the 0-672-h assessment period. CONCLUSION: Model-based simulations predicted approximately two-fold higher exposure in lighter children (20-30 kg) compared with adults. This difference was not clinically meaningful given the plateau PD effect and wide therapeutic range of triptorelin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triptorelin PamoatePuberty, PrecociousModels, BiologicalHumansChildFemaleMicrospheresLuteinizing HormoneMaleChild, PreschoolGonadotropin-Releasing Hormone

Substanzen

Triptorelin PamoateLuteinizing HormoneGonadotropin-Releasing Hormone

Autor:innen und Institutionen

  • Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, 201120, China. kun.wang@shcscc.com.
  • Shanghai Qiangshi Information Technology Co., Ltd., Shanghai, 201120, China.
  • Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, 200120, China.
  • Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai, 200120, China. zhuxiaoyan01@genscigroup.com.

ORCID-Profile: Kun Wang

Förderung

  • Changchun GeneScience

Zitieren

APA

Wang, K., Sun, Z., Xu, F., Liu, L., Luo, T., Gao, W., Zhao, T., Ma, G., & Zhu, X. (2026). Population Pharmacokinetics for Pediatric Extrapolation of GenSci006: A 3.75-mg Triptorelin Acetate Microsphere Formulation for Central Precocious Puberty. Clinical Pharmacokinetics, 65(6), 849-861. https://doi.org/10.1007/s40262-026-01634-4

Vancouver

Wang K, Sun Z, Xu F, Liu L, Luo T, Gao W, et al. Population Pharmacokinetics for Pediatric Extrapolation of GenSci006: A 3.75-mg Triptorelin Acetate Microsphere Formulation for Central Precocious Puberty. Clinical Pharmacokinetics. 2026;65(6):849-861. doi:10.1007/s40262-026-01634-4

BibTeX
@article{Wang2026,
  author = {Wang, Kun and Sun, Zhongyi and Xu, Fengyan and Liu, Lu and Luo, Tianhong and Gao, Weiwei and Zhao, Tangping and Ma, Guangli and Zhu, Xiaoyan},
  title = {Population Pharmacokinetics for Pediatric Extrapolation of GenSci006: A 3.75-mg Triptorelin Acetate Microsphere Formulation for Central Precocious Puberty},
  journal = {Clinical Pharmacokinetics},
  year = {2026},
  volume = {65},
  number = {6},
  pages = {849--861},
  doi = {10.1007/s40262-026-01634-4}
}
Kostenlos starten →